<DOC>
	<DOC>NCT00988052</DOC>
	<brief_summary>The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.</brief_summary>
	<brief_title>A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>1. Subjects must have completed the Termination visit of MSLAQ301 (completion of all Termination visit activities) according to the MSLAQ301 protocol. 2. Women of childbearing potential must practice an acceptable method of birth control [acceptable methods of birth control in this open label extension phase include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch (or hormonereleasing vaginal ring), longacting injectable contraceptive, partner's vasectomy or doublebarrier method (condom or diaphragm with spermicide)] during the study and up to 30 days after the last dose of the study drug.. 3. Subjects must be willing and able to comply with the protocol requirements for the duration of the study. 4. Subjects must be able to comprehend, sign and date a written informed consent prior to entering the MSLAQ301E study. 1. Premature discontinuation from the MSLAQ301 study, for any reason. 2. Pregnancy [according to urine dipstick Î²HCG test performed at Baseline (Month 0E) visit] or breastfeeding. 3. Subjects with clinically significant or unstable medical or surgical condition detected or worsened during the MSLAQ301 study, which preclude safe participation and completion of the MSLAQ301E study. Acute exacerbation of MS will not exclude participation in the MSLAQ301E study. 4. Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, Month 0E).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>